ABUS - Arbutus Biopharma Corporation
NASDAQ
->
Healthcare
->
Biotechnology
Warminster,
United States
Type: Equity
ABUS price evolution
ABUS
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $26.29 | $17.53 | $27.2 | $40.57 |
| Short term investments | $99.72 | $116.65 | $125.29 | $106.15 |
| Net receivables | $1.78 | $2.17 | $2.61 | $2.66 |
| Inventory | ||||
| Total current assets | $132.03 | $141.61 | $158.8 | $152.85 |
| Long term investments | $6.28 | $10.5 | $11.06 | $31.79 |
| Property, plant & equipment | $6.09 | $6.54 | $6.96 | $6.52 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $12.37 | $17.03 | $18.02 | $38.37 |
| Total investments | $106 | $127.14 | $136.34 | $137.94 |
| Total assets | $144.4 | $158.64 | $176.82 | $191.22 |
| Current liabilities | ||||
| Accounts payable | $10.27 | $9.81 | $8.8 | $9.65 |
| Deferred revenue | $11.79 | $12.11 | $15.33 | $18.35 |
| Short long term debt | $0.42 | $0.41 | $0.4 | $0.45 |
| Total current liabilities | $22.49 | $22.32 | $24.53 | $25.15 |
| Long term debt | $1.34 | $1.5 | $1.65 | $1.67 |
| Total noncurrent liabilities | $15.9 | $16.98 | $17.6 | $22.16 |
| Total debt | $1.77 | $1.91 | $2.04 | $2.12 |
| Total liabilities | $38.38 | $39.3 | $42.13 | $47.31 |
| Shareholders' equity | ||||
| Retained earnings | -$1276.65 | -$1257.34 | -$1237.24 | -$1220.14 |
| Other shareholder equity | -$48.42 | -$48.88 | -$49.47 | -$49.63 |
| Total shareholder equity | $106.02 | $119.34 | $134.69 | $143.91 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $26.29 | $30.78 | $109.28 | $52.25 |
| Short term investments | $99.72 | $116.14 | $46.03 | $71.02 |
| Net receivables | $1.78 | $1.35 | $0.9 | $1.31 |
| Inventory | ||||
| Total current assets | $132.03 | $151.14 | $160.66 | $127.7 |
| Long term investments | $6.28 | $37.36 | $35.69 | |
| Property, plant & equipment | $6.09 | $6.81 | $8.07 | $9.33 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $12.37 | $44.28 | $43.82 | $9.38 |
| Total investments | $106 | $153.5 | $81.72 | $71.02 |
| Total assets | $144.4 | $195.42 | $204.49 | $137.08 |
| Current liabilities | ||||
| Accounts payable | $10.27 | $3.52 | $10.84 | $8.9 |
| Deferred revenue | $11.79 | $22.45 | ||
| Short long term debt | $0.42 | $0.37 | $0.38 | $0.39 |
| Total current liabilities | $22.49 | $32.86 | $11.22 | $9.54 |
| Long term debt | $1.34 | $1.81 | $2.23 | $2.59 |
| Total noncurrent liabilities | $15.9 | $25.71 | $23.82 | $25.57 |
| Total debt | $1.77 | $2.19 | $2.61 | $2.98 |
| Total liabilities | $38.38 | $58.57 | $35.05 | $35.11 |
| Shareholders' equity | ||||
| Retained earnings | -$1276.65 | -$1203.8 | -$1134.35 | -$1045.96 |
| Other shareholder equity | -$48.42 | -$50.49 | -$48.34 | -$48.17 |
| Total shareholder equity | $106.02 | $136.85 | $169.44 | $101.97 |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.66 | $4.65 | $6.69 | |
| Cost of revenue | ||||
| Gross Profit | $4.66 | $4.65 | $6.69 | |
| Operating activities | ||||
| Research & development | $20.17 | $17.69 | $18.27 | |
| Selling, general & administrative | $5.84 | $5.98 | $5.55 | |
| Total operating expenses | $26.01 | $23.67 | $23.83 | |
| Operating income | -$21.35 | -$19.02 | -$17.14 | |
| Income from continuing operations | ||||
| EBIT | -$20.06 | -$16.92 | -$16.14 | |
| Income tax expense | ||||
| Interest expense | $0.05 | $0.17 | $0.2 | |
| Net income | ||||
| Net income | -$20.1 | -$17.09 | -$16.34 | |
| Income (for common shares) | -$20.1 | -$17.09 | -$16.34 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $18.14 | $39.02 | $10.99 | $6.91 |
| Cost of revenue | ||||
| Gross Profit | $18.14 | $39.02 | $10.99 | $6.91 |
| Operating activities | ||||
| Research & development | $73.7 | $84.41 | $65.5 | $47.48 |
| Selling, general & administrative | $22.48 | $17.83 | $17.14 | $14.72 |
| Total operating expenses | $96.17 | $102.24 | $82.64 | $64.25 |
| Operating income | -$78.03 | -$63.22 | -$71.65 | -$57.33 |
| Income from continuing operations | ||||
| EBIT | -$72.39 | -$63.29 | -$73.39 | -$59.73 |
| Income tax expense | $4.44 | |||
| Interest expense | $0.46 | $1.73 | $2.86 | $4.01 |
| Net income | ||||
| Net income | -$72.85 | -$69.46 | -$76.25 | -$63.74 |
| Income (for common shares) | -$72.85 | -$69.46 | -$88.39 | -$75.87 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$19.31 | -$20.1 | -$17.09 | -$16.34 |
| Operating activities | ||||
| Depreciation | $0.36 | $0.37 | $0.34 | $0.33 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.72 | $2.48 | $2.96 | $2.13 |
| Total cash flows from operations | -$17.29 | -$21.78 | -$19.56 | -$27.3 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.86 | -$0.12 | |
| Investments | $22.23 | $10.44 | $2.3 | $16.8 |
| Total cash flows from investing | $22.23 | $10.43 | $1.44 | $16.68 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.81 | $1.68 | $4.74 | $20.42 |
| Net borrowings | ||||
| Total cash flows from financing | $3.81 | $1.68 | $4.74 | $20.42 |
| Effect of exchange rate | $0.01 | $0.01 | -$0 | $0 |
| Change in cash and equivalents | $8.75 | -$9.67 | -$13.38 | $9.8 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$72.85 | -$69.46 | -$76.25 | -$63.74 |
| Operating activities | ||||
| Depreciation | $1.4 | $1.43 | $1.75 | $1.98 |
| Business acquisitions & disposals | -$2.5 | |||
| Stock-based compensation | $9.3 | $7.18 | $6.42 | $6.16 |
| Total cash flows from operations | -$85.94 | -$35.36 | -$67.53 | -$51.44 |
| Investing activities | ||||
| Capital expenditures | -$0.99 | -$0.51 | -$0.81 | -$0.23 |
| Investments | $51.76 | -$74.43 | -$11.87 | -$12.18 |
| Total cash flows from investing | $50.77 | -$74.94 | -$12.68 | -$14.91 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $30.65 | $31.81 | $137.24 | $86.75 |
| Net borrowings | ||||
| Total cash flows from financing | $30.65 | $31.81 | $137.24 | $86.75 |
| Effect of exchange rate | $0.03 | -$0.02 | $0.01 | $0.06 |
| Change in cash and equivalents | -$4.49 | -$78.51 | $57.03 | $20.45 |
News
Fundamentals
| Market cap | $463.74M |
|---|---|
| Enterprise value | $439.22M |
| Shares outstanding | 169.87M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 3.00 |
| Book/Share | 0.91 |
| Cash/Share | 0.15 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.36 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.87 |
| Quick ratio | 5.87 |